Table 1 Clinical and laboratory characteristics of the BRVO group and the macular hole group
From: Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
BRVO group | Macular hole group | Pvalue | |
|---|---|---|---|
Number† | 28 | 17 | |
Gender (Male/Female) | 17/11 | 8/9 | 0.371 |
Age (yr) | 71.2 ± 7.8‡ | 68.9 ± 6.0‡ | 0.304 |
Blood pressure (mmHg) | |||
Systolic | 135 ± 15‡ | 115 ± 14‡ | <0.001 |
Diastolic | 80 ± 10‡ | 71 ± 9‡ | 0.004 |
Hypertension | 17 | 2 | 0.001 |
Hyperlipidemia | 7 | 4 | 0.911 |
Duration of BRVO (months) | 4.7 ± 2.2‡ | - | - |
Aqueous flare (photon counts/ms) | 12.1 [8.2–14.8]‡ | 4.5 [3.9–6.1] ‡ | <0.001 |
Nonperfused area (disc area) | 44.7 ± 32.5‡ | - | - |
Foveal thickness (μm) | 557 ± 135‡ | - | - |